Delaloge S, Hurvitz S, Chan N, Bose R, Jankowitz et al. Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials. Cancer Research. 2019 79. P2-13. 10.1158/1538-7445.SABCS18-P2-13-03.
Denduluri N, Chavez-MacGregor M, Telli ML, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2018;36:2433-2443.
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:971-800.
Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Onc 2018 36:26, 2736-2740.
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):115-126.
Ibrahim E, Tripathy D, Wilkinson M, et al. Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial. Cancer Research. 2017;77(13 suppl). Abstract CT128.
Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013;14:1121-1128.
Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177-1183.
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1688-1700.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)): breast cancer. Version 1.2019. March 14, 2019. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 24, 2019.
Niraula S, Gyawali B. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;173:103-109.
Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375:11-22.
Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27-35.
Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134-141.
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380:617-628.
von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122-131.

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Moderators

Edith A. Perez, MD

Serene M. and Frances C. Durling Professor of Medicine
Mayo Clinic
Jacksonville, Florida

Disclosures

Disclosure: Edith Perez, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Daiichi Sankyo, Inc.; Genentech, Inc.; Puma Biotechnology, Inc.; Seattle Genetics, Inc.
Owns stock, stock options, or bonds from: Roche

Neelimua Denduluri, MD

Associate Chair
US Oncology Breast Research Virginia Cancer Specialists
US Oncology Network
Arlington, Virginia

Disclosures

Disclosure: Neelimua Denduluri, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Daiichi Sankyo, Inc.
Received grants for clinical research from: Daiichi Sankyo, Inc.; Genentech, Inc.; Lilly; Merck & Co., Inc.

Maire Patterson, BSN, RN, OCN

Registered Nurse
Virginia Cancer Specialists
Arlington, Virginia

Disclosures

Disclosure: Maire Patterson, BSN, RN, OCN, has disclosed no relevant financial relationships.

Editor

Angela Zimmermann, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Angela Zimmermann, PhD, has disclosed the following relevant financial relationships:
Developed content for IME or CPD activities supported by: Astra Zeneca; Merck; Novartis; Pfizer

CME Reviewer(s)

Amy Bernard, MS, BSN, RN-BC, CHCP

Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Authors: Edith Perez, MD; Neelimua Denduluri, MD; Maire Patterson, BSN, RN, OCN
CME / ABIM MOC / CE Released: 6/13/2019
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 6/13/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, surgeons, and nurses/advanced practice nurses.

The goal of this activity is to increase clinicians' knowledge and competence about the use of newer therapies in patients with human epidermal growth factor receptor (HER)2-positive early breast cancer.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Safety and efficacy data on key novel and emerging agents for early-stage HER2-positive breast cancer (BC)
Have greater competence related to:
- Individualizing adjuvant therapy based on patient and tumor factors in patients with early-stage HER2-positive BC
- Coordination of care within the interdisciplinary BC treatment team
Have greater confidence related to:
- Using strategies to help engage patients with HER2-positive BC in their treatment selection and ongoing

Disclosures

Moderators

Edith A. Perez, MD

Serene M. and Frances C. Durling Professor of Medicine
Mayo Clinic
Jacksonville, Florida

Disclosures

Disclosure: Edith Perez, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Daiichi Sankyo, Inc.; Genentech, Inc.; Puma Biotechnology, Inc.; Seattle Genetics, Inc.
Owns stock, stock options, or bonds from: Roche

Neelimua Denduluri, MD

Associate Chair
US Oncology Breast Research Virginia Cancer Specialists
US Oncology Network
Arlington, Virginia

Disclosures

Disclosure: Neelimua Denduluri, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Daiichi Sankyo, Inc.
Received grants for clinical research from: Daiichi Sankyo, Inc.; Genentech, Inc.; Lilly; Merck & Co., Inc.

Maire Patterson, BSN, RN, OCN

Registered Nurse
Virginia Cancer Specialists
Arlington, Virginia

Disclosures

Disclosure: Maire Patterson, BSN, RN, OCN, has disclosed no relevant financial relationships.

Editor

Angela Zimmermann, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Angela Zimmermann, PhD, has disclosed the following relevant financial relationships:
Developed content for IME or CPD activities supported by: Astra Zeneca; Merck; Novartis; Pfizer

CME Reviewer(s)

Amy Bernard, MS, BSN, RN-BC, CHCP

Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Authors: Edith Perez, MD; Neelimua Denduluri, MD; Maire Patterson, BSN, RN, OCNFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 6/13/2019

Valid for credit through: 6/13/2020

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CME / ABIM MOC / CE Information

Activity transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderators

Edith A. Perez, MD

Neelimua Denduluri, MD

Maire Patterson, BSN, RN, OCN

Editor

Angela Zimmermann, PhD

CME Reviewer(s)

Amy Bernard, MS, BSN, RN-BC, CHCP

CME / ABIM MOC / CE

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Target Audience and Goal Statement

Disclosures

Moderators

Edith A. Perez, MD

Neelimua Denduluri, MD

Maire Patterson, BSN, RN, OCN

Editor

Angela Zimmermann, PhD

CME Reviewer(s)

Amy Bernard, MS, BSN, RN-BC, CHCP

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer